Vol 11, No 6 (2015)
Case report
Published online: 2016-03-08
Page views 400
Article views/downloads 1392
Get Citation

Connect on Social Media

Connect on Social Media

Prolonged-release oxycodone/naloxone in the treatment of cancer pain — a case report

Aleksandra Modlińska
Oncol Clin Pract 2015;11(6):326-329.

Abstract

In moderate and strong cancer pain oxycodone has become one of the most effective and popular opioids. A combination of prolonged-release oxycodone with prolonged-release naloxone is a valued option among patients suffering from pain and opioid–induced bowel dysfunction (OIBD).
We present a case of a male cancer patient with chronic constipation effectively treated with oxycodone/naloxone
combination.

References

  1. Ciałkowska-Rysz A, Dzierżanowski T. Podstawowe zasady farmakoterapii bólu u chorych na nowotwory i inne przewlekłe, postępujące, zagrażające życiu choroby. Med Paliat. 2014; 6: 1–6.
  2. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006; 10(4): 287–333.
  3. Cleeland CS, Nakamura Y, Mendoza TR, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995; 61(2): 277–284.
  4. Caraceni A, Hanks G, Kaasa S, et al. European Palliative Care Research Collaborative (EPCRC), European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012; 13(2): e58–e68.
  5. van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007; 18(9): 1437–1449.
  6. Gardiner C, Gott M, Ingleton C, et al. Attitudes of health care professionals to opioid prescribing in end-of-life care: a qualitative focus group study. J Pain Symptom Manage. 2012; 44(2): 206–214.
  7. Coluzzi F, Mattia C. Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol. 2005; 71(7-8): 451–460.
  8. Wang YM, Liu ZW, Liu JL, et al. Efficacy and tolerability of oxycodone in moderate-severe cancer-related pain: A meta-analysis of randomized controlled trials. Exp Ther Med. 2012; 4(2): 249–254.
  9. Zacny JP, Gutierrez S. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology (Berl). 2003; 170(3): 242–254.
  10. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology. 2003; 60(6): 927–934.
  11. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001; 182(5A Suppl): 11S–18S.
  12. Rosti G, Gatti A, Costantini A, et al. Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur Rev Med Pharmacol Sci. 2010; 14(12): 1045–1050.
  13. Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007; 61(7): 1181–1187.
  14. Ueberall MA, Müller-Lissner S, Buschmann-Kramm C, et al. The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res. 2011; 39(1): 41–50.
  15. Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965; 150(3699): 971–979.
  16. Hermanns K, Junker U, Nolte T. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study. Expert Opin Pharmacother. 2012; 13(3): 299–311.
  17. Schutter U, Grunert S, Meyer C, et al. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin. 2010; 26(6): 1377–1387.
  18. Abramowitz L, Béziaud N, Caussé C, et al. Further validation of the psychometric properties of the Bowel Function Index for evaluating opioid-induced constipation (OIC). J Med Econ. 2013; 16(12): 1434–1441.
  19. Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med. 2012; 26(1): 50–60.
  20. Ahmedzai SH, Leppert W, Janecki M, et al. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer. 2015; 23(3): 823–830.
  21. Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract. 2010; 64(6): 763–774.
  22. Löwenstein O, Leyendecker P, Lux EA, et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol. 2010; 10: 12.